Novel schemes of administration of multitherapies useful for the treatment of people affected by Human Immunodeficiency Virus (HIV)

摘要

Pharmaceutical composition for the treatment of human immunodeficiency virus (HIV) in humans comprising three or four active ingredients chosen as follows: - a nucleosidic reverse transcriptase inhibitor (INTI) selected from lamivudine and emtricitabine; - another nucleoside or nucleotide reverse transcriptase inhibitor (INTI) chosen from didanosine, abacavir and tenofovir; and - the combination of ritonavir with a protease inhibitor (PI) chosen from lopinavir, fosamprenavir, atazanavir and darunavir; or a non-nucleosidic reverse transcriptase inhibitor (INNTI) chosen from efavirenz, and etravirine; for a daily administration one to four days a week to said human being.